These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38923416)

  • 1. Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.
    Neve M; Diderichsen PM; Helmer E; de Vries D; Taneja A
    ACR Open Rheumatol; 2024 Jun; ():. PubMed ID: 38923416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Denton CP; Furst DE; Mayes MD; Matucci-Cerinic M; Smith V; de Vries D; Ford P; Bauer Y; Randall MJ; Ebrahimpoor M; Kupcsik L; Stiers PJ; Deberdt L; Prasad N; Lim S; Pujuguet P; Ahmed S
    Arthritis Rheumatol; 2023 Aug; 75(8):1434-1444. PubMed ID: 36787101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
    Ebata S; Yoshizaki A; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Okiyama N; Kodera M; Hasegawa M; Sato S
    Lancet Rheumatol; 2022 Aug; 4(8):e546-e555. PubMed ID: 38294008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
    Chung L; Spino C; McLain R; Johnson SR; Denton CP; Molitor JA; Steen VD; Lafyatis R; Simms RW; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Sandorfi N; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Allanore Y; Matucci-Cerinic M; Whitfield ML; Distler O; Singer O; Young A; Nagaraja V; Fox DA; Furst DE; Khanna D
    Lancet Rheumatol; 2020 Dec; 2(12):e743-e753. PubMed ID: 34966900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
    Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.
    Allanore Y; Distler O; Jagerschmidt A; Illiano S; Ledein L; Boitier E; Agueusop I; Denton CP; Khanna D
    Arthritis Rheumatol; 2018 Oct; 70(10):1634-1643. PubMed ID: 29732731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis.
    Ledoult E; Launay D; Béhal H; Mouthon L; Pugnet G; Lega JC; Agard C; Allanore Y; Jego P; Fauchais AL; Harlé JR; Berthier S; Aouba A; Mekinian A; Diot E; Truchetet ME; Boulon C; Duhamel A; Hachulla E; Sobanski V;
    Arthritis Res Ther; 2020 Feb; 22(1):30. PubMed ID: 32070422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
    Maher TM; Ford P; Brown KK; Costabel U; Cottin V; Danoff SK; Groenveld I; Helmer E; Jenkins RG; Milner J; Molenberghs G; Penninckx B; Randall MJ; Van Den Blink B; Fieuw A; Vandenrijn C; Rocak S; Seghers I; Shao L; Taneja A; Jentsch G; Watkins TR; Wuyts WA; Kreuter M; Verbruggen N; Prasad N; Wijsenbeek MS;
    JAMA; 2023 May; 329(18):1567-1578. PubMed ID: 37159034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study.
    Mihai C; Dobrota R; Assassi S; Mayes MD; Distler O
    ACR Open Rheumatol; 2020 Aug; 2(8):496-502. PubMed ID: 32720753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
    Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
    Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
    Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
    Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
    Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
    Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
    Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
    Chen C; Wang L; Wu J; Lu M; Yang S; Ye W; Guan M; Liang M; Zou H
    Front Pharmacol; 2022; 13():805708. PubMed ID: 35177989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.